Enlivex Therapeutics Ltd
ENLV1.490USD
+0.040+2.76%
Market hours （ET）Quotes delayed by 15 min
35.54MMarket Cap
LossP/E TTM
More Details of Enlivex Therapeutics Ltd Company
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Company Info
Ticker SymbolENLV
Company nameEnlivex Therapeutics Ltd
IPO dateJul 30, 2014
CEODr. Oren Hershkovitz, Ph.D.
Number of employees36
Security typeOrdinary Share
Fiscal year-endJul 30
Address14 Einstein St.
CityNESS-ZIONA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code7403618
Phone97286623301
Websitehttps://www.enlivex.com/
Ticker SymbolENLV
IPO dateJul 30, 2014
CEODr. Oren Hershkovitz, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
Dr. Oren Hershkovitz, Ph.D.
Dr. Oren Hershkovitz, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Baruch Halpert
Mr. Baruch Halpert
Director
Director
--
--
Sangwoo Lee
Sangwoo Lee
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 23
Updated: Fri, May 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
7.47%
Novik (Shai A)
3.60%
Millennium Management LLC
2.81%
Morgan Stanley Smith Barney LLC
0.96%
Havron (Abraham)
0.76%
Other
84.40%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
7.47%
Novik (Shai A)
3.60%
Millennium Management LLC
2.81%
Morgan Stanley Smith Barney LLC
0.96%
Havron (Abraham)
0.76%
Other
84.40%
Shareholder Types
Shareholders
Proportion
Hedge Fund
11.45%
Individual Investor
4.61%
Investment Advisor
1.41%
Research Firm
0.47%
Investment Advisor/Hedge Fund
0.10%
Other
81.96%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
48
4.30M
18.04%
-270.43K
2025Q1
51
5.97M
25.02%
-258.45K
2024Q4
49
6.10M
27.74%
+737.29K
2024Q3
43
5.25M
23.90%
+285.76K
2024Q2
47
4.79M
22.40%
+1.35M
2024Q1
46
3.03M
14.05%
-328.65K
2023Q4
48
2.85M
15.31%
-503.64K
2023Q3
50
3.93M
21.15%
-597.01K
2023Q2
52
3.97M
21.39%
-603.59K
2023Q1
56
4.01M
21.61%
-571.54K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
1.78M
7.47%
-426.07K
-19.30%
Mar 31, 2025
Novik (Shai A)
858.77K
3.6%
+84.74K
+10.95%
Mar 31, 2025
Millennium Management LLC
669.01K
2.81%
+35.16K
+5.55%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
229.73K
0.96%
-38.97K
-14.50%
Mar 31, 2025
Havron (Abraham)
181.46K
0.76%
+1.92K
+1.07%
Mar 31, 2025
Renaissance Technologies LLC
181.29K
0.76%
+22.30K
+14.02%
Mar 31, 2025
Jane Street Capital, L.L.C.
80.76K
0.34%
+67.89K
+527.35%
Mar 31, 2025
Citadel Advisors LLC
70.14K
0.29%
+70.14K
--
Mar 31, 2025
Hershkovitz (Oren Ph.D.)
42.05K
0.18%
+16.55K
+64.92%
Mar 31, 2025
ESALIENS TFI SA
40.00K
0.17%
--
--
Dec 31, 2023
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
